Poster
Molecular Analysis of Circulating Tumor DNA in Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC Treated With Mobocertinib
Author
Sylvie Vincent
Condition
non–small cell lung cancer
Drug target
EGFR exon 20 insertion mutations
Drug moa
tyrosine kinase inhibition
Source url
s3://convoke-optic-posters/2024-05-10/Vincent et al. Molecular analysis of ctDNA in EGFR Exon 20+ NSCLC. Poster presented at ASCO 2022.pdf
1 organization
1 product
Product
Mobocertinib